Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.46 AUD
Change Today -0.005 / -1.08%
Volume 186.0K
As of 1:10 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

31 Dalgleish Street

Thebarton, SA 5031


Phone: 61 8 8354 6100

Fax: 61 8 8354 6199

Bionomics Limited engages in the discovery and development of therapeutics in the areas of cancer, multiple sclerosis, anxiety, and epilepsy in Australia and France. Technologies MultiCore MultiCore technology is a suite of methods for the chemical synthesis of complex drug-like molecules with ring structures that is the structure of many marketed drugs, and naturally occurring bioactive molecules. The company applies its MultiCore technology to the production of compound libraries in this complex molecular space that focus on the target of interest and are weighted towards drug-like characteristics. Angene: Proprietary technology behind BNC105 The company’s drug discovery platform Angene incorporates a variety of tools and models of angiogenesis (the formation of new blood vessels) for drug target validation and drug discovery in cancer and inflammation. IonX IonX is an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development activities. IonX includes systems for high throughput electrophysiology for early, high content evaluation of drug hits. Collaborations/Partnerships Bionomics’ Merck Serono partnership: Bionomics’ Merck Serono partnership is a fully funded collaboration, covered by an R&D and licensing agreement. The collaboration represents the validation of Bionomics’ chemistry platform, Multicore, and know how in ion-channel biology, covered by the company’s IonX technology. Bionomics subsidiary Neurofit is also active in the collaboration with Merck Serono. The partnership involves the preclinical development of Kv1.3 as a target for the treatment of multiple sclerosis. Cancer Therapeutics Co-operative Research Centre: The company is a participant and shareholder of the Cancer Therapeutics Co-operative Research Centre (CTx). CTx is focused on the discovery and early development of small molecule drugs for the treatment of cancer. CTx has a specific focus on small molecule cancer drugs or enabling therapeutics for single or co-therapy regimes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.46 AUD -0.005

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies

Industry Analysis


Industry Average

Valuation BNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at